A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

What this study is about

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Who can join (things the study team will check)

✅ You may be able to join if…

• Males \& females (inclusive of all gender identities) age ≥18 years
• BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence
• Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
• History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime

🚫 You may not be able to join if…

• Obesity primarily caused by other endocrine disorders
• History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening
• Significant hepatobiliary disease and/or any of the following results at Screening:
  • ALT ≥ 3.0 × ULN
  • AST ≥ 3.0 × ULN
  • TBL > 1.5 × ULN (except for cases of known Gilbert's Syndrome)
• Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Where this trial is running

• Research Site, Dothan, Alabama, United States
• Research Site, Huntsville, Alabama, United States
• Research Site, Mesa, Arizona, United States
• Research Site, Escondido, California, United States
• Research Site, Clearwater, Florida, United States
• Research Site, Jacksonville, Florida, United States
• Research Site, Stockbridge, Georgia, United States
• Research Site, Champaign, Illinois, United States
• Research Site, Chicago, Illinois, United States
• Research Site, Ames, Iowa, United States
• Research Site, Troy, Michigan, United States
• Research Site, Jefferson City, Missouri, United States

+ 200 more sites.

Who to contact

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07784725.